Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus DYCLOPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus DYCLOPRO.
CHILDREN'S MOTRIN vs DYCLOPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
50 mg intravenously every 8 hours
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Category C
Category C
NSAID
NSAID